<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Eighty-one consecutive <z:chebi fb="0" ids="44423">hydroxyurea</z:chebi>-treated patients with Philadelphia (Ph) chromosome negative <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_512'>myeloproliferative disease</z:mpath> were followed prospectively from 1981 to 1989; 35 of them had <z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera, 32 had <z:e sem="disease" ids="C0040028" disease_type="Disease or Syndrome" abbrv="">essential thrombocythemia</z:e>, 12 had <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo>, and 2 had myeloproliferative syndromes </plain></SENT>
<SENT sid="1" pm="."><plain>The 81 patients were treated with <z:chebi fb="0" ids="44423">hydroxyurea</z:chebi> for a total of 3,804 months during the observation time </plain></SENT>
<SENT sid="2" pm="."><plain>Only three patients had been treated with <z:chebi fb="0" ids="22333">alkylating agents</z:chebi> or <z:chebi fb="0" ids="37972">32P</z:chebi> before start of <z:chebi fb="0" ids="44423">hydroxyurea</z:chebi> treatment </plain></SENT>
<SENT sid="3" pm="."><plain>Four patients transformed into <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> or <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo>; three of these patients had <z:e sem="disease" ids="C0040028" disease_type="Disease or Syndrome" abbrv="">essential thrombocythemia</z:e>, and one had a myeloproliferative syndrome </plain></SENT>
<SENT sid="4" pm="."><plain>Two patients died of solid <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Five out of 53 evaluable patients (9%) had pretreatment clonal cytogenetic abnormalities involving chromosomes 1, 9, 20, and 21 </plain></SENT>
<SENT sid="6" pm="."><plain>At follow-up, during or after <z:chebi fb="0" ids="44423">hydroxyurea</z:chebi> treatment, 15% had cytogenetic abnormalities, an unexpectedly low frequency compared to the previously reported frequency in patients with <z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera treated with <z:chebi fb="0" ids="22333">alkylating agents</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>None of our patients who developed cytogenetic clonal changes during <z:chebi fb="0" ids="44423">hydroxyurea</z:chebi> therapy had <z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera </plain></SENT>
<SENT sid="8" pm="."><plain>However, follow-up is too short to draw any conclusions about the mutagenic potential of <z:chebi fb="0" ids="44423">hydroxyurea</z:chebi> compared to <z:chebi fb="0" ids="22333">alkylating agents</z:chebi> </plain></SENT>
</text></document>